Collagen type III alpha 1 chain mRNA (COL3A1 mRNA)

COL3A1 mRNA encodes the pro-alpha1 chain of type III collagen, a major fibrillar collagen essential for the structural integrity of extensible tissues like blood vessels, skin, and internal organs (MedlinePlus, 2017). It is a significant therapeutic target in both genetic and acquired diseases. In Vascular Ehlers-Danlos Syndrome (vEDS), mutations in the COL3A1 gene lead to defective mRNA and protein, causing life-threatening tissue fragility; allele-specific silencing of the mutant mRNA is a key research strategy to restore normal collagen ratios (NIH, 2024). In fibrotic diseases and certain cancers, overexpression of COL3A1 mRNA contributes to excessive extracellular matrix deposition and chemoresistance, making its downregulation a therapeutic goal (PubMed, 2024). Current drug development focuses on RNA-based modalities, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), to modulate its expression levels (ResearchGate, 2019). These therapies aim to either degrade the mRNA or modulate its splicing to produce functional or reduced protein levels. However, therapeutic intervention must be carefully balanced, as excessive reduction of type III collagen can lead to vascular instability and organ rupture (AHA Journals, 2024).

Other names

Collagen alpha-1(III) chain mRNAProcollagen type III alpha 1 mRNAEDS4A mRNAAlpha-1 type III collagen mRNA

RNA interference (siRNA), Antisense inhibition (ASO), Splice modulation (exon skipping), mRNA degradation, and Translation inhibition.